KAICO Ltd., founded in 2018, is a pioneering Japanese biotechnology startup that leverages its proprietary silkworm-baculovirus expression system to develop and produce recombinant proteins. By utilizing silkworms as bioreactors, KAICO offers a scalable and speedy solution for protein production, bypassing the need for traditional bio tanks.
The company's innovation centers around the development of oral vaccines for humans and animals, aiming to transform global health and increase livestock productivity. Oral vaccines present significant advantages, such as eliminating the need for syringes, medical personnel, and cold-chain logistics. This approach positions KAICO to potentially revolutionize healthcare access worldwide.
Recently, KAICO secured a ¥540.00M Series B investment on 01 April 2025, highlighting investor confidence in its transformative potential within the Biotechnology and Pharmaceutical industries.